Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma

Leuk Lymphoma. 2020 Nov;61(11):2767-2770. doi: 10.1080/10428194.2020.1783442. Epub 2020 Jul 7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bispecific* / therapeutic use
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Non-Hodgkin*
  • Neoplasm Recurrence, Local / drug therapy

Substances

  • Antibodies, Bispecific
  • blinatumomab